Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 13/20 | 0.56 |
| ▸ | HTR2A | P28223 | 11/20 | 0.56 |
| ▸ | KCNH2 | Q12809 | 10/20 | 0.54 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.49 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.47 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.43 |
| ▸ | RIPK1 | Q13546 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22957691 | 0.84 | NTRK1 (0.44) | SLC6A4HTR2AKCNH2NTRK1ALDH1A1 | |
| SCHEMBL22957694 | 0.82 | MCL1 (0.58) | SLC6A4HTR2AKCNH2SLC6A2SLC6A3 | |
| SCHEMBL22957926 | 0.81 | NTRK1 (0.43) | SLC6A4HTR2AKCNH2NTRK1ALDH1A1 | |
| SCHEMBL18588991 | 0.81 | SLC6A4 (0.59) | SLC6A4HTR2AKCNH2SLC6A2SLC6A3 | |
| SCHEMBL22957708 | 0.80 | NTRK1 (0.42) | SLC6A4HTR2AKCNH2NTRK1ALDH1A1 | |
| SCHEMBL29746979 | 0.80 | SLC6A4 (0.66) | SLC6A4HTR2AKCNH2NTRK1SLC6A2 | |
| SCHEMBL3124150 | 0.80 | SLC6A4 (0.66) | SLC6A4HTR2AKCNH2NTRK1SLC6A2 | |
| SCHEMBL28613921 | 0.80 | ALDH1A1 (0.44) | SLC6A4HTR2AKCNH2NTRK1ALDH1A1 | |
| SCHEMBL24180218 | 0.79 | PPARG (0.40) | NTRK1ALDH1A1 | |
| SCHEMBL22390440 | 0.79 | NTRK1 (0.40) | NTRK1ALDH1A1RIPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3580220-B1 | AMINOTRIAZOLOPYRIDINES AS KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2021-11-17 | — | — | EP | disclosed |
| US-10913738-B2 | Aminotriazolopyridines as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-02-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10913738-B2 | Aminotriazolopyridines as kinase inhibitors | RIPK1, RIPK3, RIPK4 | SLC6A4 3049/4885HTR2A 2314/4885KCNH2 1920/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.